DFTX Stock Forecast: Definium Therapeutics, Inc. Price Predictions for 2026-2027
The 19 Wall Street analysts covering Definium Therapeutics, Inc. hold a median 12-month price target of $71 — +150.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 50 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Definium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
DFTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DFTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +150.4% from it.
Of the 20 most recent actions, 13 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | JP Morgan | Maintains | Overweight | $84 → $85 |
| 10 Nov 2026 | RBC Capital | Maintains | Outperform | $66 → $70 |
| 9 Oct 2026 | JP Morgan | Initiates | Overweight | — |
| 15 Sept 2026 | Baird | Maintains | Outperform | $75 → $79 |
| 15 Sept 2026 | Canaccord Genuity | Maintains | Buy | $64 → $78 |
| 14 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $70 |
| 14 Sept 2026 | Needham | Reiterates | Buy | $66 |
| 11 Sept 2026 | RBC Capital | Reiterates | Outperform | $66 |
| 18 Aug 2026 | B of A Securities | Initiates | Buy | $75 |
| 14 Aug 2026 | Maxim Group | Maintains | Buy | — |
| 13 Aug 2026 | Baird | Maintains | Outperform | $57 → $75 |
| 13 Aug 2026 | Canaccord Genuity | Maintains | Buy | $58 → $64 |
| 13 Aug 2026 | Jones Trading | Maintains | Buy | $74 → $90 |
| 13 Aug 2026 | RBC Capital | Maintains | Outperform | $57 → $66 |
| 13 Aug 2026 | Wells Fargo | Maintains | Overweight | $68 → $72 |
| 12 Aug 2026 | Needham | Maintains | Buy | $50 → $66 |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | $73 → $75 |
| 27 July 2026 | Wells Fargo | Initiates | Overweight | $68 |
| 24 July 2026 | Piper Sandler | Reiterates | Overweight | $48 → $73 |
| 8 July 2026 | Stifel | Maintains | Buy | $30 → $60 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DFTX.
This page is one stock. Monday covers all of them.
DFTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
DFTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Definium Therapeutics, Inc. returned +160.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
DFTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 4.0×
- EV / EBITDA
- —
Cheaper than 23% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −61.4%
- Return on assets
- −24.2%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Definium Therapeutics, Inc. has a market value of $3.9B and an enterprise value of $2.9B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$353.8M.
Free cash flow in the twelve months to 30 June 2026: −$168.0M.
Definium Therapeutics, Inc. employs 105 people.
Data provided by Twelve Data
DFTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at DFTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Definium Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about DFTX
What is the DFTX stock price forecast for 2026-2027?
The 19 Wall Street analysts covering Definium Therapeutics, Inc. have a median 12-month price target of $71, with estimates ranging from $55 to $91. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DFTX stock a buy right now?
Of the 19 analysts covering Definium Therapeutics, Inc., 19 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Definium Therapeutics, Inc. 50 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DFTX?
As at 21 Nov 2026, Definium Therapeutics, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
Will DFTX stock go up?
No one can know that. What the data says: the median 12-month target from 19 analysts implies +150.4% from the last close, and Ticker Nerd's factor model ranks Definium Therapeutics, Inc. 50 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DFTX stock forecast for 2030?
No analyst covering Definium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DFTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $91 over the next 12 months.
How has DFTX stock performed over the past year?
Definium Therapeutics, Inc. returned +160.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Definium Therapeutics, Inc. do?
Definium Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders. The company’s current pipeline centers on psychiatry and neurology, with lead product candidates such as DT120, an orally disintegrating tablet under late-stage study for generalized anxiety disorder and major depressive disorder, and DT402, which is being evaluated for autism spectrum disorder.
About Definium Therapeutics, Inc.
Definium Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders. The company’s current pipeline centers on psychiatry and neurology, with lead product candidates such as DT120, an orally disintegrating tablet under late-stage study for generalized anxiety disorder and major depressive disorder, and DT402, which is being evaluated for autism spectrum disorder. Definium Therapeutics applies a research-driven approach to psychedelic-derived and other brain-health-focused therapeutics, aiming to address underlying causes of psychiatric and neurological conditions. The company operates from New York and serves the healthcare and biotechnology markets through its drug development programs and clinical research activities.
CEO Mr. Robert Barrow · 105 employees · United States · https://definiumtx.com